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ABSTRACT 
Background: Osteosarcoma (OS) is the most predominant bone tumor in 
individuals between 10-25 yrs of age. Cisplatin is the most widely used 
chemotherapeutic agent for OS management, it significantly enhances the survival 
rate. Resistance to the drug, toxicities of high doses and metastasis are the major 
concerns in the treatment. 
Objective: Our primary objective is to investigate effects of calcitriol in 
combination with cisplatin on the osteosarcoma cell apoptosis, invasion and 
migration. Our hypothesis is pretreatment of OS cells with calcitriol would 
sensitize them for cisplatin therapy leading to decrease in concentration for IC50. 
Secondary objective was to evaluate the effect of calcitriol on migration and 
invasion of OS cell lines, and the role of matrix metalloproteins (MMPs) in 
migration/invasion. 
Design: Previous findings in our lab suggests, calcitriol act as differentiation 
agent in human osteosarcoma cell lines 143B and SaOS-2. The dose response of 
cisplatin with and without calcitriol (100nM) pretreatment was studied in 
osteosarcoma cell lines 143B-MM, 143-P and control murine osteoblast MC3T3-
E1. Cell proliferation and sensitization effects were evaluated by MTS assay. 
Boyden chamber assay was used for migration/invasion studies. MMP activity 
was measured using Sensolyte kit and real time PCR for the detecting the 
expression of MMP-1.  
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Results: Calcitriol does not sensitize the 143B-P and 143B-MM OS cells for 
cisplatin therapy. Calcitriol sensitization inhibits the migration of 143B-P cells in 
matrigel whereas no significant difference was observed in control and calcitriol 
treated 143B-MM cells. Calcitriol pretreatment does modulate MMP-1expression 
in 143B-P OS cells.  
Conclusion:  Calcitriol pretreatment does not sensitize OS cells to chemotherapy 
but, has an effect on the migration and invasion of 143B-P OS cell line. 
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ABBREVIATIONS 
OS: Osteosarcoma 
143B-P: 143B parental human OS cell line 
143B-MM: 143B metastatic cell lines derived from mice 
VDR: vitamin D receptor 
1,25D: 1α, 25-dihydroxyvitamin D3 
ATCC: American Type Culture Collection 
DMEM: Dulbecco’s Modified Eagle’s Medium 
FBS: Fetal bovine serum 
HBSS: Hank’s Balanced Saline Solution 
MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) 
1α- OHase/CYP27B1: 1α-hydroxylase 
24α-OHase: 24α-hydroxylase 
RT-PCR: Reverse Transcriptase Polymerase Chain Reaction 
MMP: Matrix Metalloprotein
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INTRODUCTION 
Osteosarcoma (OS) is the primary bone malignancy affecting children and 
adolescents especially from ages 10-20yrs, typically occurs in long bones such as 
femur, tibia and humerus (1). It develops from blocked differentiation in 
malignant mesenchymal cells.  Microscopically, OS is identified by the presence 
of rapidly proliferating cells and synthesis of abundant osteoid or un-mineralized 
matrix (2). There are approximately 400 new cases each year in United States and 
the frequency of occurrence is higher in boys than girls (3). Incidence of OS in 
adults is associated with Paget’s disease and other risk factors include hereditary 
disorders, Li-Fraumeni syndrome, retinoblastoma, fibrous dysplasia, ionizing 
radiations and history of bone disorders (7).  Clinical symptoms of OS include 
pain, swelling, palpable mass, weight loss and pathologic fractures in 10-15% of 
population. Diagnosed with lab results of elevated alkaline phosphatase or lactate 
dehydrogenase or both, diagnostic scans such as computerized tomography (CT), 
radio nucleotide, and positron emitted tomography (PET) are helpful in 
identifying treatment response and follow up recurrences (9).  Current therapy 
against OS includes surgery and multi-agent chemotherapy regimen with drugs 
such as doxorubicin, cisplatin, methotrexate and ifosamide; this enhances the 
overall survival rate by more than 50% (8), but there still remain 33% of OS 
patients who do not respond to the existing chemotherapy. Despite the advances 
in treatment since the last two decades, about 30-40% of the cases results in 
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relapse (5). About 90% relapses culminate in pulmonary/lung metastasis, a 
common cause of death in OS patients (6).  Novel treatment regimens are 
necessary for the patients who are not responsive to the existing therapies and for 
those who have recurring OS. Reducing the complications and toxic side effects 
associated with chemotherapy is a challenging goal in OS treatment or 
management. Newer treatment strategies include designing new chemotherapeutic 
agents with less toxicity and high efficacy or use of agents to overcome 
chemoresistance by sensitizing tumor cells to chemotherapeutic drugs at lower 
concentrations (7, 8, 9).  The key for devising effective treatment modalities for 
OS include identification of relevant biological targets such as genes and 
signaling pathways in response to chemotherapeutic drugs (10). Application of 
drugs such as interferons (INF-α), interleukins, bisphosphonates, monoclonal 
antibodies to sensitize the OS cells to undergo chemotherapy induced apoptosis is 
known (11). 
Vitamin D has a major physiological role in bone metabolism (12). There is an 
increasing evidence of the anti-cancer properties of active form of vitamin D, 
calcitriol [1α,25-dihydroxyvitamin D3]. Relationship between the status of 25-
hydroxyvitamin D3 (25(OH)D3), the circulating form of vitamin D and cancer 
occurrence is reported in several studies (13). Calcitriol can exhibit anti-
neoplastic activity by blocking the cell cycle growth, inducing differentiation or 
apoptotic genes (14). Calcitriol has potentiating action on anti-cancer effects of 
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chemotherapeutic agents (15). Calcitriol induces cell differentiation in cancer 
cells, arrests proliferation and suppresses cell cycle and reduces cancer cell 
survival time. Differentiation pathways of calcitriol vary in different cancer types. 
For example, in breast and prostate cancers, calcitriol exerts antiproliferative and 
apoptotic effects on the cell lines (16).  
The anti-neoplastic effects of calcitriol in OS are not well studied. Calcitriol can 
be a modulator of disease and might act at one or all stages of cancer. Vitamin D 
receptor (VDR)  plays a role in differentiation and anti-proliferative effects of 
calcitriol in OS by modulating the genes involved in cell cycle, angiogenesis and 
apoptosis, ligand binding to VDR is essential to mediate the antineoplastic effects 
of calcitriol (14,16). 
Osteosarcoma is not radiosensitive and high doses of chemotherapeutic agents are 
used for treatment (11). Therapeutic approaches promoting the differentiation 
may be very effective as OS primarily occurs because of a block in the 
differentiation of mesenchymal stem cells. Evidence suggests the potentiating 
activity of calcitriol to the chemotherapeutic agents in various cancers such as 
prostate, colon, breast and blood cancers (15).  Sensitization effect of calcitriol in 
OS to chemotherapeutic agents needs to be clearly investigated.   
JUSTIFICATION:  
Previous reports including the studies from our lab suggests calcitriol at 100nM 
dose can induce differentiation and apoptosis in different OS cell lines (40). 
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Expression of genes encoding for VDR, 1 α-hydroxylase (1 α OHase) and 24-
hydroxylase (24-OHase)  in response to calcitriol treatment in the OS cell lines 
and over expression of 24-OHase in the tissue microarrays were observed in 
previous experiments in Dr. Garimella’s lab. Calcitriol enhanced differentiation in 
143B, a highly metastatic; K-ras mutated human OS cell line. 
Resistance to chemotherapy is the major concern in OS. Cisplatin resistance 
might be acquired or intrinsic. Other possible mechanisms for chemoresistance 
can be genetic mutations, expression of apoptotic genes and proteins and rapid 
detoxification of the drug in vivo. Sensitization of recalcitrant cancer cells to 
chemotherapy is a potential strategy to overcome the chemoresistance. 
Sensitization effect of calcitriol on chemotherapeutic response is evident in 
certain cancer cell lines (57-59). However, it is not known whether such an effect 
exists in OS. With the known role of calcitriol in bone metabolism and in OS cell 
lines, sensitization should be beneficial in minimizing the resistance to 
chemotherapy and resulting in decreased cancer cell viability, invasion and 
migration. The results obtained from this study, if significant will provide 
valuable information regarding the role of calcitriol as a chemosensitization agent 
and elucidate the underlying potential mechanism decreasing the 
chemotherapeutic doses required. Understanding the mechanism underlying 
metastasis is necessary to improve the treatment protocol and this reduced the 
relapse rates, as 90% relapses are due to metastasis.  
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STUDY OBJECTIVES: The study objectives were: 
 Evaluation of the sensitization effect of calcitriol for cisplatin therapy on 
OS cell apoptosis migration, and invasion.  
 Establishing the mechanism for the sensitization comparing the changes 
between calcitriol treated and untreated cell lines.  
RESEARCH QUESTION: 
Primary: a) Does calcitriol pre-treatment sensitize OS cells for cisplatin therapy? 
b) Does calcitriol pre-treatment inhibit migration of OS cells? 
Secondary:  
a) At what concentration is sensitization achieved?  
b) Does the mechanism of sensitization involve modulation of caspases?  
c) Is migration regulated via matrixmetalloproteins (MMPs)? 
HYPOTHESIS: 
Our hypothesis is calcitriol pretreatment will sensitize OS cells to cisplatin, thus 
decreasing the inhibitory concentration (IC50) for cisplatin. We anticipate, 
calcitriol will sensitize OS cells to cisplatin via modulation of caspase expression 
and inhibits migration of cancer cells by down regulation of matrix 
metalloproteins (MMPs).  
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Figure 1: Schematic representation of the hypothesized mechanism of 
sensitization effect of calcitriol to cisplatin therapy 
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LITERATURE REVIEW 
Osteosarcoma: Osteosarcoma (OS) is the most common primary bone tumor in 
children and adolescents from ages 10-25yrs with about 500 cases reported 
annually (1-3, 65). The etiology of OS is multi-factorial, characterized mainly by 
invasion and metastasis along with other factors (2, 3, 7, 8). The factors 
associated with OS are environmental such as exposure to radiation and beryllium 
oxide (2); epidemiological including associations with diseases such as 
retinoblastoma, Bloom syndrome and genetic impairments such as defects in cell 
cycle regulation with Rb/p53 mutations (2, 3).  Pathogenesis of OS is attributed to 
aberrations in cell cycle and transcriptional regulations, genomic integrity 
maintenance, and increased migration, invasion and chemoresistance (3, 4). 
With the current treatment options, surgery and multi drug chemotherapy survival 
rate is at 70% (5, 65). Most effective chemotherapeutic agents against OS include 
high doses of methotrexate plus cisplatin, doxorubicin or ifosfamide. High doses 
of multiple chemotherapeutic agents are prescribed to increase survival rate. The 
adverse effects associated with the high doses of chemotherapeutic agents include 
cardiac toxicity, acute and chronic nephrotoxicity, neurotoxicity, ototoxicity, 
infertility and malignant secondary tumors (9-12). Progression of OS and 
metastasis involve neovascularization, proliferation, invasion, apoptosis, 
resistance and advances to sites such as lungs, kidneys and liver (3, 6, 25, 26). 
Metastasis is the major causative factor for relapse and other complications 
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including drug resistance (24). Novel treatment regimens such as therapies 
including tumor modulating or differentiating agents are very much necessary for 
patients who develop resistance or for those who are not responsive for the 
present therapies.  
Vitamin D: Vitamin D is a fat soluble vitamin, found in cod liver oil, fish, 
fortified milk and cereals. It is a secosteroid and functions as a prohormone. Pre-
vitamin D3 or vitamin D3 obtained from exposure to sun or diet is converted in to 
25-(OH)-D3 in the liver by the enzyme 25-hydroxylase.  In the kidney, 25-(OH)-
D3 is hydroxylated to 1,25-(OH)2D3 by the enzyme 1-α-hydroxylase. The major 
circulating form is 25-(OH)-D3 and the functional form is 1,25-(OH)2D3 
(calcitriol). Vitamin D is essential for calcium homeostasis and its deficiency is 
characterized by inadequate mineralization of bone, leading to acute 
consequences on bone health such as rickets or osteomalacia (64). Role of vitamin 
D is well established in the bone metabolism and in various cancers such as breast 
(15, 22, 59) and prostate (36, 44, 53).   
The major physiological function of vitamin D is to regulate serum calcium 
concentration. This is achieved by increasing intestinal calcium absorption. 
Vitamin D stimulates osteoclastogenesis from monocyte precursors in the 
presence of receptor activator of nuclear factor kappa-B ligand (RANKL). 
Activated or mature osteoclasts actively resorb bone mineral and release calcium, 
thus maintaining blood calcium levels. Parathyroid hormone (PTH) secreted by 
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chief cells of parathyroid gland, regulates blood calcium and phosphorous levels. 
When blood calcium levels are low, PTH promotes bone resorption, decreases 
renal calcium excretion and increases 1-α-hydroxylase levels, increasing calcitriol 
production. PTH secretions are decreased when blood calcium levels are high.  
Increased secretions of PTH are often associated with vitamin D deficiency and 
renal defects (64). Hence, vitamin D deficiency causes secondary 
hyperparathyroidism results in loss of phosphorus by PTH (16). Low calcium and 
phosphorus concentrations lead to mineralization defects developing rickets.  
Circulating levels of 25 (OH)-D are the best indicators of vitamin D levels. The 
expression of vitamin D receptor is present in small intestine, colon, osteoblasts, 
osteoclasts, activated T and B lymphocytes, pancreas, brain, heart, skin, gonads, 
breast, prostate and mono nuclear cells (15, 22).  
Physiological aspects of vitamin D metabolism are presented in the figure 2 (13).  
 In addition to the role in bone mineral homeostasis, vitamin D has other non-
calcemic actions such as thyroid function (17), insulin secretion (18), modulation 
of lymphocyte function and immune function (19), cellular differentiation and 
proliferation (23), effects on myocardial contractility (20), etc. 
Calcitriol (1,25-(OH)2D3),  major circulating form of vitamin D, exerts 
antineoplastic activity via genomic or non-genomic mechanisms in various 
cancers such as prostate, breast, colon, and blood cancers (29).  
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 Figure 2: Schematic representation of Vitamin D metabolism 
In genomic pathway gene transcription regulation is achieved by hetero-
dimerization of vitamin D receptor (VDR) with nuclear retinoid X receptor 
(RXR). In non-genomic pathway calcitriol modulates the functions of calcium 
channels. Calcitriol mediates the transcriptional and post-transcriptional control of 
the gene expression in various cancers.  Calcitriol induces cell differentiation in 
cancer cells, arrests proliferation and suppresses cell cycle and reduces cancer cell 
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survival time by regulating the transcription factors such as ubiquitous AP-1 
complex. Non-genomic functions of vitamin D include intestinal calcium 
absorption, bone mineralization by acting of osteoblasts, opening of voltage gated 
calcium and chloride channels, activation of kinases and phospholipases (30, 31). 
Differentiation pathways of calcitriol vary in different cancer types. For example, 
in breast and prostate cancers, calcitriol exerts anti-proliferative and apoptotic 
effects (31-34).    
The transcriptional and post-transcriptional control of the gene expression in 
various cancers may be mediated by vitamin D. Vitamin D receptor aids in 
transcription functions of vitamin D modulating the expression of genes involved 
in cell cycle. Calcitriol mediated differentiation effects may be cell specific. For 
example in monocytic cells, calcitriol induces differentiation in two phases. In the 
first phase expression of monocytic phenotype markers occur and this phase lasts 
for 24-48h while the cells continue in the normal cell cycle. Second phase 
involves in blocking G1 to S phase in cell cycle. In breast and prostate cancers, 
calcitriol exerts anti-proliferative and apoptotic effects on the cell lines (24-31).  
Administration of calcitriol in early stages exerted better anti-tumor activity than 
in later stages. Calcitriol functions via VDR regulating cell proliferation, 
apoptosis angiogenesis, and promotes differentiation in colorectal cancer (34). In 
ovarian cancer 1α,25-hydroxyvitamin D3 induces apoptosis by destabilizing 
telomerase reverse transcriptase (21). Vitamin D increases vascular endothelial 
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growth factor (VEGF) in smooth muscles and upregulates mRNA of potent anti-
angiogenic factor thrombospondin in human colon cancer cells (47). The 
mechanism underlying vitamin D mediated effects in cancer cell differentiation, 
proliferation, apoptosis and angiogenesis do not follow a particular pattern 
demonstrates heterogeneity in vitamin D effects or heterogeneity due to inherent 
cancer cell biology (33). Hence, it is suggests the potentiating action of vitamin D 
on anti-cancer effects of chemotherapeutic agents.  
Vitamin D and Osteosarcoma: Characteristic knockdown of CYP27B1 in 
human OS cell lines resulted in proliferation (35); incubation with vitamin D 
resulted in promoted mineralization (36).  
Vitamin D modulates gene transcription in osteoblasts producing matrix proteins 
such as osteopontin, osteocalcin, osteonectin play a key role in bone mass 
formation (33, 34). Hara K et al reported the oral administration of 1α-
hydroxyvitamin D3 inhibits tumor growth and metastasis in Dunn OS cell lines 
(35).  
Vitamin D at concentrations from 10nM to 100nM induced differentiation in 
human OS cell lines 143B, SaOS-2 (33, 40). Expression of several differentiation 
markers such as osteocalcin, alkaline phosphatase, bone gla proteins increased in 
relation to dose of vitamin D (38). Osteocalcin, alkaline phosphatase (ALP) and 
bone gla proteins are directly related to degrees of osteogenesis indicating bone 
differentiation. Expression of differentiation markers is an important aspect for 
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calcitriol use in OS. Calcitriol treatment significantly reduced caspases activity in 
UMR 106 cell lines (37).  
Cisplatin and Calcitriol in cancer: Cisplatin is the most commonly used drug to 
treat various types of cancers. Toxicity, tumor resistance and poor bioavailability 
are the undesirable features of cisplatin therapy.  Cisplatin toxicities with high 
doses include neurotoxicity leads to hypokalemia, hypocalcemia and 
hypomagnesemia, ototoxicity and infertility in males (9). Resistance to cisplatin is 
the major concern in the treatment of cancers with cisplatin. Cisplatin acts by 
binding to DNA of the cancerous cell leading to lesions in DNA. Cisplatin 
resistance may arise due to copper transporters or because of intensified activation 
by thiol molecules such as glutathione or metallothionein. Cisplatin resistance in 
ovarian, cervical, lung and bladder cancer can be attributed to increased 
glutathione levels. Tumor suppressor protein p53 inactivation, survivin 
expression, decreased accumulation and apoptosis signaling proteins also lead to 
decreased cisplatin resistance (38, 39).  
Calcitriol enhances the anti-neoplastic activity of various cytotoxic or 
chemotherapeutic agents. Ying yu et al studied calcitriol effects on various 
cancers in combination with chemotherapeutic agents such as cisplatin, 
carboplatin, doxorubicin, fluorouracil, gemcitabine, paclitaxel and docetaxel (31). 
Calcitriol potentiates cisplatin/carboplatin in breast and prostate cancer. Calcitriol 
pre-treatment sensitized squamous cell carcinoma cells to cisplatin therapy and 
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promotes cytotoxicity of fluorouracil in colon cancer. The mechanisms of action 
for enhancing the activity are different in each cancer (46). Combination of 
vitamin D with cytostatics reduced the inhibitory concentration (IC50) values in 
cancers sensitive to vitamin D such as squamous cell carcinoma (44) breast (59), 
colon (47) and prostate cancers (42). Use of hypocalcemic vitamin D synthetic 
analogues in sensitization experiments is beneficial owing to their less toxic 
effects (35).  
Moffatt et al reported elevated growth inhibition of prostate cancer cells was 
observed in the combination therapy of higher concentrations of vitamin D and 
lower concentrations of platinum drugs (42). Potentiating effect of calcitriol on 
cisplatin was investigated by Hershberger et al. They reported the role of mitogen 
activated protein kinase kinase (MEKK-1) pathway mediates cisplatin induced 
apoptosis by calcitriol pretreatment in squamous cell carcinoma (43). From the 
above literature we can infer, calcitriol and cisplatin act synergistically in certain 
cancers. 
Resistance to chemotherapy, toxicities of the chemotherapeutic agents and high 
recurrence rates in OS put forth a challenge of sensitization of cancerous cells in 
order to provide improved treatment regimes. Commonly used treatment regimes 
are not effective in leukemia with myeloid/lymphoid or mixed lineage leukemia 
(MLL) gene. Hence, inducing differentiation is a useful strategy in such cases. All 
trans retinoic acid (ATRA) and calcitriol were used to induce differentiation in 
15 
 
combination with 5-aza-2’- deoxycytidine therapy. Both ATRA and calcitriol 
potentiated the effect of 5-aza-2’- deoxycytidine in MLL gene chemoresistant 
leukemia (45). Sensitization may induce apoptosis along with differentiation in 
various cancers. Calcitriol sensitization induces caspase independent apoptosis in 
colon and breast cancer cells.  In breast cancer cells, the production of enzymatic 
protein cathepsin B and tumor necrosis factor receptor I (TNF-RI) are increased. 
The mechanisms of differentiation induced by vitamin D and TNF-α are different, 
combination of these agents enhanced apoptosis (46, 47). Sensitization of OS 
cells to chemotherapy is an ongoing process in OS management. Literature 
suggests the sensitization of OS cell lines with bone anabolic agents such as 
statins for example; atrovastatin and bisphosphonates for e.g. zoledronic acid are 
effective in enhancing the chemotherapeutic response (49, 51). Olivia et al found 
atrovastatin induced sensitization of OS cell lines in combination with 
doxorubicin treatment decreased cell viability and migration (49). Zou et al 
reported sensitization of OS cell line is by down regulating an apoptosis inhibitor 
protein, survivin (50). 
The mechanism for the sensitization by calcitriol may be via regulation of 
caspases. Caspases are cysteine-aspartate proteases with an important role in 
apoptosis. Regulation of caspase dependent apoptosis with calcitriol sensitization 
was reported in squamous cell carcinoma, prostate and breast cancer (31, 37, 43, 
44, 50).   
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Matrix metalloporteins: Matrix metalloproteins (MMP) are zinc dependent 
proteases, play a vital role in cell proliferation, migration, invasion, differentiation 
and apoptosis by degradation of extra cellular matrix (12, 29, 54). There are more 
than 20 types of MMPs and role of MMPs in tumors are well studied (61). Several 
MMPs are over expressed in bone and cartilage, for example MMP-9 and MMP-
13. Over expression of MMP-12 in colon cancer, MMP-3 in breast and prostate 
cancer, MMP-2 in bone, prostate and squamous cell carcinoma are reported; 
altered rate in survival and metastasis was attributed to MMP-9 in prostate and 
OS (52-59). Down regulation of MMP-1 and MMP-9 by calcitriol and its 
analogues in breast cancer cell lines was reported (58, 59). Modulation of MMP-
13 and MMP-1 expression by calcitriol in osteoblast like cells was reported (56, 
60-62). Kimura et al reported role of MMP-1 in 143B cell invasion, and 
pulmonary metastasis of OS (63). However, modulation of expression of different 
MMPs by calcitriol is not clearly investigated and is a subject of intense research 
in understanding OS pathobiology and disease management.  
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Gaps in research: 
Calcitriol is a potent differentiation inducing agent in OS. There not much 
information available in the current literature in support of calcitriol and OS 
treatment. The mechanism for resistance in OS needs to be addressed and 
thoroughly investigated for devising effective chemotherapy. There is emphasis 
on calcitriol sensitization in breast, colon and prostate cancers in literature. The 
anti-apoptotic activity of calcitriol should be studied further and the mechanism of 
sensitization should be made clear.  
Differentiation and anti-proliferation effects of calcitriol are well established. 
Recent research shows sensitization of OS cell lines with bone anabolic agents 
such as statins, bisphosphonates enhances the anti-neoplastic activity of 
chemotherapeutic agents. The aim of the present study is to evaluate the effects of 
sensitization of OS cell lines with calcitriol prior to cisplatin treatment and 
examine its effects on migration, invasion and apoptosis.  
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METHODS 
Setting: All experiments were carried out at The University of Kansas Medical 
Center (KUMC) in lab 1006 Briendenthal Annex and the Department of Dietetics 
and Nutrition. 
Ethics: This study qualifies for the exemption from Human Subjects Approval as 
the cell lines used in these in vitro experiments are considered as secondary data. 
The cell lines used in this study contain no identifying marker, available publicly 
and are obtained from American Type Culture Collection (ATCC).  
Materials:  
Cell lines: Osteosarcoma (OS) cell lines 143B parental (143B-P), 143B 
metastatic murine (143B-MM) and MC3T3-E1 (mouse pre-osteoblast) were used 
in the study. 143B cell lines are K-ras and P53 gene mutated. 143B-MM is 
metastatic version of 143B, obtained from metastatic lung lesions of in vivo 
bioluminescent orthotopic OS mouse (BOOM) model. Both the OS cell lines are 
highly proliferative and metastatic. 
Cell Cultures: Osteosarcoma and osteoblast cells were cultured and maintained 
in Dulbecco’s’ Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal 
Bovine Serum (FBS), 5% Penicillin/Streptomycin, 5% Amphotericin, 5 % L-
glutamine and 5% non-essential amino acids. The cells were maintained in a 
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humid incubator at 37
o
C with 95% air and 5% CO2. Medium was changed for 
every 3 days. 
Reagents: Calcitriol was purchased from Enzo Life Sciences International Inc., 
(Plymouth Meeting, PA) and cisplatin 1mg/ml was purchased from KUMC 
pharmacy. Stock solutions of calcitriol was prepared in ethanol and cisplatin in 
dye free DMEM. Calcitriol aliquots were stored at -20
o
C and cisplatin at room 
temperature.  
Data collection procedures: For the experiments confluent OS cells and 
osteoblasts were harvested by Trypsin digestion (trypsinization) of the adherent 
cell cultures. Following trypsinization, the cells were counted using trypan blue in 
hemocytometer. Trypan blue is a dye used to stain the dead/non-viable cells. 
Viable (unstained) and non-viable (stained) cells were counted in three different 
quadrants of hemocytometer (n=3). A defined number of cells were seeded in 96-
well/24well/6-well plates or T75 flasks. The average number of cells per ml was 
calculated using the following formula: 
Cells per ml = Average number of cells (in three quadrants) x 2500 x 10 
Where 2500 is the area and 10 is the dilution factor. 
Cell viability assay: CellTiter 96® AQueous One Solution Cell Proliferation 
Assay (MTS assay) and colony formation assay are used for the evaluation of cell 
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proliferation and viability. MTS assay is a colorimetric method to determine the 
number of viable cells. Mitochondrial activity of the cells when MTS tetrazolium 
compound is converted into formazan on reaction with dehydrogenase enzyme is 
measured. Viable cells convert the MTS to formazan, whereas non-viable/dead 
cells do not. The IC50 value of cisplatin for the above OS cell lines is determined 
from dose response curves using (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay. Ten 
thousand cells per well were plated in 96-well plates, after 24h when the cells 
were confluent calcitriol and cisplatin were added. Different concentrations of 
cisplatin are represented as C1 (50nM), C2 (100nM), C3 (250nM) and C4 
(500nM) were used in each row. After 48h of incubation with calcitriol/cisplatin 
the medium was aspirated, 100µl of fresh medium and 20µl of MTS reagent were 
added. Cell viability was evaluated after 1hour of incubation using a microplate 
reader at 490nm. 
Control Calcitriol 
100nM 
C1  
50nM 
C2 
100nM 
C3 
250nM 
C4 
500nM 
MTS assay 
C1, C2, C3 and C4 represent four different concentrations of cisplatin. 
 
          (A)             (B)                           (C)     (D) 
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(A) Represents cell plating 
(B) Addition of cisplatin/calcitriol after 24h 
(C) Addition of MTS reagent after 48h 
(D) Terminating the reaction and reading absorbance after 1h. 
The MTS assay was also used to evaluate sensitization effects of calcitriol apart 
the cisplatin dose response. Ten thousand cells per well were plated in 96-well 
plates and 100nM calcitriol was added after 24h. After 24h of addition of 
calcitriol, four different concentrations of cisplatin were added to the cells and 
incubated for 48h. The cells in 96well plate are treated with MTS reagents and 
read at 490nm in a spectrophotometer.  
Cntrl Calcitriol 
100nM 
Cal. + C1 
Cal.@100nM 
C1@50nM 
Cal. + C2 
Cal.@100nM 
C2@100nM 
Cal.+ C3 
Cal.@100nM 
C3@250nM 
Cal. + C4 
Cal.@100nM 
C4@500nM 
Cal. stands for Calcitriol and C1, C2, C3 and C4 for different concentrations of 
cisplatin. 
 
Colony formation assay: It is a gold standard technique used to determine the 
cytotoxic effect of the chemotherapeutic agent. For this assay, 10,000 cells per 
well were seeded in 6-well plates and calcitriol (100nM) was added at confluence 
(48h). After 48h exposure to calcitriol, cisplatin was added and the cells were 
incubated for 48h. The medium was aspirated and cells were washed three times 
with phosphate buffer solution (PBS). The cells were fixed with 
22 
 
paraformaldehyde and stained with crystal violet. The stain was extracted by 1% 
acetic acid and quantified at 570nM. 
Control Calcitriol  
100nM 
Calcitriol + C3  
Cal.@100nM               
C3 @250nM 
Calcitriol + C4  
Cal. @ 100nM 
C4 @ 500nM 
Control Calcitrol 
100nM 
C3 
250nM 
C4 
500nM 
C3 and C4 for different concentrations of cisplatin 
Migration assay: The effect of calcitriol on migration of OS cell lines was 
studied using Boyden-Chamber method. Osteosarcoma and osteoblast cells were 
pre-treated with calcitriol for 72h. Calcitriol pre-treated and untreated (control) 
cells were plated in the inserts placed in 24-well plates. Five thousand cells were 
plated in the inserts and after 24h; the cells were fixed with ethanol and stained 
with crystal violet. The number of crystal violet stained cells were quantified 
colorimetrically at 560nm following extraction with 1% acetic acid. 
Control  Calcitriol treated 100nM 
Control (in the 
insert) 
 
Calcitriol treated 100nM (in 
the insert) 
 
 
Invasion assay: Collagen and matrigel were used to study the invasive effects of 
OS and osteoblast cells. Matrigel was used to simulate the tumor micro-
environment and collagen for bone micro-environment. The inserts were coated 
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with collagen/matrigel and incubated for 30mins. After collagen/matrigel 
polymerization, coated inserts were conditioned with serum free medium for 1h. 
Five thousand cells per insert were plated and after 48h invaded cells on the 
bottom of the insert were stained with crystal violet subsequent extraction and 
detection at 560nm was carried out.  
Matrix metalloprotein spectrophotometric assay: Matrix metalloproteins 
(MMPs) are membrane associated zinc endopeptidases with a significant role in 
wound healing, arthritis and cancer. SensoLyte Generic MMP assay kit was used 
for MMP activity evaluation. Cells treated with and without calcitriol were 
washed with HBSS; 10µg/ml of Trypsin was added and incubated for 1h. Trypsin 
inhibitor was added after 1h at 100µg/ml concentration for 15mins. MMP 
substrate solution, MMP inhibitor and diluents were prepared. The test 
components were added into the microplate along with the controls in triplicates. 
The plate was read for kinetics at 37
o
C absorbance at 412nm and data is recorded 
every 10mins for 1h. Glutathione reference standard was used for instrument 
calibration with concentrations 100, 50 and 25 µM.  
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR):  
Total RNA isolation: For RNA isolation, 2.5 x 10
4
 cells were plated in 6-well 
plate and calcitriol 100nM was added to the three wells at confluence having 
control and calcitriol treated samples. After 72h of calcitriol addition total RNA 
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was isolated from the cells by Qiagen RNeasy mini kit and stored at -20
o
C. The 
ratio of absorbance at 260/280 was used to measure the purity of RNA and the 
samples with ratio of approximately 2 and nothing less than 1.85 were used for 
PCR.  
Reaction mix for PCR: 
Component Quantity  
Sybr green 12.5µl 
Primer A 1.25µl 
Primer B 1.25µl 
Reverse Transcriptase 0.25µl 
Template RNA Variable (100-500ng) 
RNA free water Up to 25µl 
 
The real time PCR was performed using iCycler (Bio-rad) at Dr. Rowe’s lab. (Dr. 
Peter Rowe, Kidney Institute, University of Kansas Medical Center). The 
program used for PCR was: 
Step Time Temperature 
Reverse transcription 30mins 50
o
C 
Initial PCR activation 15mins 95
o
C 
Denaturation 1min 94
o
C 
Annealing 1min 60
o
C 
Extension 1min 72
o
C 
 
Denaturation, annealing and extension steps were repeated for 40cycles with final 
extension time of 10mins at 72
o
C.   
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Relative expression between samples was calculated using Livak’s equation    
Xn= 2
-ΔΔC
T . Xn is the relative amount of target genes and ΔCT is difference 
between cycle threshold of the test gene (MMP-1) and reference gene (GAPDH). 
Statistical analysis: Microsoft excel was used for statistical analysis. Mean, 
standard deviation, variance and standard error was calculated for all the data. 
Paired t-test and single factor analysis of variance (ANOVA) were used to 
analyze the difference between control and experimental data. The P value of less 
than 0.05 was considered statistically significant.  
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RESULTS 
The purpose of this study was to investigate the sensitization effects of 
calcitriol on OS cells for cisplatin therapy. The effect of calcitriol on 
proliferation and migration of OS cells lines 143B-P, 143B-MM and 
MC3T3-E1, murine osteoblast control were analyzed. The cell line 143B-
P is parental human OS cell line with K-ras and p53 mutations.  
Cell proliferation was measured using MTS assay. The cells were cultured 
for 4 days with different concentrations of cisplatin to establish IC50, the 
doses of cisplatin required to inhibit half the cell population. The 
concentration of cisplatin required to significantly inhibiting the 
proliferation of both 143B-P and 143B-MM cell lines were 500nM. On the 
other hand, this dose of cisplatin was ineffective on control osteoblast cell 
line MC3T3-E1 (Figure 3). 
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(B)  
   
(C) 
 
Figure 3: Dose response of cisplatin on the cell lines, (A) MC3T3-E1 (B) 
143B-P and (C) 143B-MM. Cell proliferation measured after 96h 
treatment with 100nM calcitriol / varying concentrations of cisplatin. 
 Represents statistical significance with P < 0.05.   
 
Sensitization effect of calcitriol on the OS cell lines for cisplatin therapy 
was studied using MTS assay and colony formation assay. Pretreatment of 
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OS cells with calcitriol did not have any significant sensitization effects 
for cisplatin therapy at all tested doses. There was no significant 
sensitization effect of calcitriol on either of the cell lines. (Figure 4) 
(A) 
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(C)                                      143B-MM MTS assay 
 
Figure 4: Sensitization effect of calcitriol for cisplatin therapy on the cell 
lines, (A) MC3T3-E1 (B) 143B-P and (C) 143B-MM. Cells were 
sensitized with 100nM calcitriol for 48h prior to cisplatin treatment and 
cell proliferation was measured after 48h treatment with varying 
concentrations of cisplatin. Represents statistical significance with 
P<0.05.  Significance was found in regard with cisplatin treatment at the 
highest dose but not for calcitriol’s sensitization effects. 
 
Sensitization effects of calcitriol were also evaluated using high doses of 
calcitriol such as 500nM and 1µM. Cisplatin dose of 500nM was used as it 
corresponds to IC50 in our studies. No significant sensitization effects were 
observed with either of the doses.  
Colony formation assay, a gold standard technique for cytotoxicity 
determination. No significant sensitization effects of calcitriol were 
observed in either of the cell lines (Figure 5). 
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(A) MC3T3-E1 
 
 
(B) 143B-P 
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(C) 143B-MM 
 
Figure 5: Effect of calcitriol on sensitization of (A) MC3T3-E1 (B) 143B-
P (C) 143B-MM to cisplatin treatment by colony formation assay. 
Calcitriol at 100nM concentration was used and Cis-1= 50nM, Cis-
2=100nM, Cis-3=250nM and Cis-4=500nM. 
 
Migration and Invasion: Effects of calcitriol on migration and invasion of 
OS cell lines 143B-P and 143B-MM, and control osteoblast were 
investigated using Boyden-chamber method. 
Calcitriol exerted a significant effect on the migration of 143B-P cell line 
in comparison with control (P<0.5). In 143B-MM and control osteoblast 
MC3T3-E1 cell lines, there was no significant difference between treated 
and untreated groups (Figure 6). 
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(B) 143B-P  
 
(C) 143B-MM 
                
Figure 6: Representative photomicrographic illustration showing the effect of 
calcitriol on the migration of (A) MC3T3-E1 osteoblast cells (B) 143B-P and (C) 
143B-MM. Control and calcitriol pretreated cells were plated in the inserts, 
incubated for 24hrs and stained with crystal violet for 20mins. Stained cell were 
imaged at 10X magnification and the bound stain was extracted with 1%acetic 
acid. 
 
The migration data was quantified by extraction with acetic acid and 
absorbance was read at 570nm (Figure 7). 
 
Calcitriol Control 
Control Calcitriol 
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Figure 7: Effect of calcitriol on migration of osteoblast and OS cell lines. 
Control and calcitriol sensitized cells were cultured in the inserts for 96h; 
the inserts were stained with crystal violet for 20mins and the bound stain 
was extracted from the cells with 1% acetic acid. Absorbance of the 
extract was read at 570nm.     Indicates statistical significance P < 0.05.  
 
Invasiveness of the cell lines was studied using rat tail collagen type I and 
matrigel. Calcitriol treatment significantly inhibited invasion of 143B-P 
cells in matrigel. In collagen we observed decreased mobility of calcitriol 
treated control (untreated) osteoblast MC3T3-E1 (Figure 8). 
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(ii) Collagen  
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(ii) Collagen 
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(C) 143B-MM 
(i) Matrigel 
         
(ii) Collagen 
      
Figure 8: Representative photomicrographic illustration showing the 
effect of calcitriol on invasion of  (A) MC3T3-E1 osteoblast cells (B) 
143B-P and (C) 143B-MM though (i) matrigel and (ii)collagen. Inserts 
were coated with either matrigel or collagen for 1h and cells were plated 
and after 96h incubation inserts were washed and stained with crystal 
violet. The stained inserts were imaged at 10X magnification and stain 
was extracted with 1% acetic acid.  
 
The crystal violet stains were quantified by extraction with 1% acetic acid 
and absorbance was read at 570nm. (Figure 9) 
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(A) Matrigel: 
 
(B) Collagen: 
 
Figure 9: Effect of calcitriol on invasion of OS cells and osteoblasts in 
two different types of extracellular membranes molecules (A) Matrigel 
simulates tumor microenvironment and (B) Collagen, simulates bone 
microenvironment. Calcitriol sensitization decreased invasion of 143B-P 
cells in matrigel. Represents statistical significance with P < 0.05.  
 
 
When collagen and matrigel membranes were compared for invasiveness 
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difference was observed between control OS cells whereas, in calcitriol 
sensitized OS cells we find no difference in  invasion of cells in both the 
membrane simulators. In calcitriol treated osteoblast we observed a 
significant decrease in invasion in collagen membrane (Figure 10).  
       
                      
 
Figure 10: Comparison between matrigel and collagen membrane for 
invasiveness of (A) Control and calcitriol treated OS and osteoblast (B) 
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comparison between the membranes.  represents statistical significance 
P < 0.05. 
 
Matrix metalloprotein expression: Sensolyte generic MMP assay kit was 
used for spectrophotometric analysis of MMP 1,2,3,7,8,9,12,13 and 14. 
No significant differences were observed between calcitriol treated and 
untreated samples, though a slight decrease in calcitriol treated 143B-P 
was observed   (Figure 11). 
 
Figure 11: MMP activity kinetics analyzed with Anaspec generic MMP 
kit. Calcitriol pretreatment does not significantly decrease the MMP 
activity.  
 
Real time RT-PCR assays were performed used two different sequences of 
MMP-1. Primer sequence-1 (PS1) was reported sequence by Kimura et al 
and primer sequence-2 (PS-2) is the sequence designed in our lab using 
Roche software (Appendix D). There were no significant differences in 
the expression of MMP-1 mRNA in calcitriol treated and control 
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(untreated) 143B-P cells with the reported sequence whereas, using our 
primer we did see a significant decrease in the expression of MMP-1 in 
calcitriol pretreated 143B-P cell line (Figure 12).  
(a) Primer sequence 1(PS1) 
 
(b) Primer sequence 2 (PS2) 
 
Figure 12: (a) Comparison of MMP-1 mRNA expression in control vs. 
calcitriol pretreated 143B-P OS cells using RT-PCR with reported PS-1 
(b). Comparison of MMP-1 mRNA expression in control vs. calcitriol 
pretreated 143B-P OS cells using RT-PCR with PS-2 our design (N = 5 
with triplicates every time).    Indicates significance with P < 0.05. 
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DISCUSSION 
Resistance to chemotherapy is the major concern in OS and sensitizing these cells 
should be beneficial strategy in the treatment protocol. Literature suggests 
calcitriol sensitization is an effective method in treating cancers such as breast, 
prostate and colon (15, 42, 47, 59). The previous findings in Dr. Garimella’s lab 
suggest the presence of VDR and vitamin D responsive target genes in OS cells.  
In this study, we demonstrated calcitriol pretreatment for 48h does not sensitize 
OS cells 143B-P or 143B-MM for cisplatin therapy using MTS and colony 
formation assays. Inhibitory concentration (IC50) of cisplatin was established by 
dose response MTS assay with all the three cell lines (Fig. 2A, 2B, 2C). 
 Cisplatin’s IC50 for 143B-P and 143B-MM was 500nM and at this dose 
osteoblast cells remained unaffected. Cisplatin concentrations ranging from 100ng 
to 20µM were used in different variety of OS cell lines such as U2OS and SaOS-2 
(49, 51).  High dose requirements of cisplatin may be due to the different 
mutational backgrounds or inherent heterogeneity among subpopulations of OS 
cells. SaOS-2 and U2OS are p53 null, whereas, 143B is K-ras gene mutated.  
Calcitriol sensitization occurs via arresting G1/ G2 phase in cell cycle   in prostate 
cancer (42, 58); increasing caspase activation in colon cancer (47); and increasing 
mitogen activated protein kinase kinase expression in squamous cell carcinoma 
(43). In our studies no sensitization effect of calcitriol was observed in 143B OS 
cells.  Higher doses calcitriol, 500nM and 1000nM (1µM) were also studied and 
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no sensitization effect was observed in OS cells. Calcitriol pretreatment for 48h 
was not appropriate time period to observe sensitization effects on OS cells. Other 
pretreatment times such as 72h and 96h need to be studied to obtain 
comprehensive data for the effects of sensitization.  
Using the gold standard method, i.e. colony formation assay we examined the 
sensitization effect of calcitriol on OS cells. In accord with MTS assay results we 
observed no sensitization effect of calcitriol pre treatment in OS cells. The 
increase in proliferation as seen in Cal+C1, Cal+C3 and Cal+C4 vs. C1 or C3 or 
C4 (cisplatin alone) treatments for MC3T3-E1 cells is most likely due to rapid 
proliferative response of osteoblasts to calcitriol pretreatment, during the initial 
growth phase (30,31).  
The cell line 143B-MM was obtained from the lungs of mice by inducing OS with 
143B-P cell injection after metastasis. Though the origin of both 143B-P and 
143B-MM cell lines is human OS, 143B-MM and 143B-P might differ 
biologically. These biological differences in the cell lines may account for the 
variation in migration of OS cells. 143B-MM cell characterization would be 
beneficial in understanding the mechanism of migration and invasion and 
response to chemotherapeutic/tumor modulating agents. 
Calcitriol mediated different effects on migration of 143B-P and 143B-MM OS 
cells.  While calcitriol exerted a significant effect on 143B-P cells, no significant 
effect was observed in 143B-MM and MC3T3-E1 cell lines.  
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The effect of calcitriol on the invasiveness of the OS cells lines was studied in 
matrigel and collagen. Matrigel is a commercially available reagent and it mimics 
the extracellular matrix of the tumor micro environment, thus providing the 
cancer cells with chemoattractants and growth factors such as epidermal, insulin 
like and fibroblast growth factor (66) for optimum growth. Collagen is the most 
abundant protein in mammals and a major component of connective tissue helps 
in protecting the cell integrity. Type 1 collagen simulates bone micro environment 
and acts as a chemotactic agent (67, 68). In matrigel, untreated OS and osteoblast 
cells along with calcitriol treated osteoblast cell invasion was significantly 
increased when compared to collagen. This may be attributed to the presence of 
growth factors in matrigel.  
Calcitriol pretreatment significantly decreased invasion of 143B-P OS cells in 
both collagen and matrigel. In 143B-MM cell line the decrease in invasiveness 
upon calcitriol pretreatment was not significant. Increase in sample size for 143B-
MM may yield significant results.   
We hypothesized calcitriol sensitization regulates MMPs as MMPs are key 
mediator of cancer cell migration and invasion (58, 59, 61). Previous studies have 
demonstrated the importance of MMP-9, MMP-13 and more recently role of 
MMP-1 is evident in stimulating OS migration, invasion and metastasis (53, 60, 
63) there by suggesting MMPs as important biomarkers and potential therapeutic 
targets in OS disease management. Kimura et al (63) reported enhanced 
43 
 
expression of MMP-1 in 143B, and the role of c-jun and Fra-1 in inducing MMP-
1 expression.  
Calcitriol pretreatment of OS cells did not regulate MMP activity (Fig 11). 
The failure to detect MMP activity in calcitriol treated and untreated 143B-P cells 
using the MMP generic kit may be due to the presence of an unknown inhibitor in 
the reaction mixture containing crude OS cell extracts prepared from trypsin 
digestion.  Hence, we used real time PCR to detect the expression of MMP-1 
mRNA. MMP-1 was reported to be abundantly expressed in 143B OS cell lines 
(63). Previously reported Kimura et al sequence and a sequence designed by our 
lab were used to evaluate the expression of MMP-1 in calcitriol treated and 
untreated 143B-P OS cell line. In RTPCR experiment we used only one OS cell 
line 143B-P as the significant differences between control and calcitriol 
treatments in migration and invasion studies were evident in only143B-P cell line. 
In RT-PCR experiment calcitriol treatment did not affect the expression of 
reported sequence of MMP-1 whereas, with the PS-2 we see a significant 
decrease in MMP-1 expression on calcitriol treatment in 143B-P OS cell line (Fig 
12). This suggests the role of other proteins such as MMP-9, MMP-13 and MMP-
28 or CXCR4 in vitamin D mediated effects on the migration and invasion of 
143B-P need to be investigated. 
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Conclusion: 
This study investigated the effect of calcitriol pretreatment on 143B-P & 143B-
MM OS cells and MC3T3-E1 osteoblast control. Though there are reports 
suggesting calcitriol sensitization for chemotherapy in different cancers, we did 
not find any sensitization effects of calcitriol on OS cells.  
Calcitriol pretreatment was effective in inhibition of migration and invasion of 
143B-P cells but not in 143B-MM cells. The effect of calcitriol on MMP1 mRNA 
expression was variable. With the reported primer sequence no significant 
difference in calcitriol induced changes in MMP1 expression was observed where 
as with the newly designed primer sequence, we observed a statistically 
significant change in the MMP-1 expression of calcitriol treated 143B P OS cells. 
Limitations: 
This an in vitro study where tumor micro environment complexity is 
compromised. Artificial substrates for physiological fluids such as FBS or 
reagents such as matrigel for simulating cytokines and growth factors present in 
tumor microenvironment are used. Heterogeneity in cancer cells can induce 
variable responses in terms of sensitization and chemotherapy. For sensitization 
experiments we used a single time point (48h) of calcitriol pretreatment. Increase 
in the exposure time to calcitriol might sensitize the OS cells for chemotherapy. 
Expression of MMP is regulated by various factors such as growth factors, cell-
cell and cell-extra cellular membrane interactions. In migration and invasive 
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studies collagen and matrigel might have contributed for the regulation in MMP 
expression along with calcitriol. The sample size was small; replication of the 
experiments for MMP activity assay with protein measurement should be carried 
out. We analyzed only MMP-1 using PCR, evaluation of other MMPs should be 
done in order to understand the mechanism for migration and invasion.  
Future directions: 
In vivo studies are necessary to understand the role of calcitriol in inhibiting the 
tumor progression and metastasis in OS. Additional time points such as 72h and 
96h should be included for complete evaluation of sensitization effect of calcitriol 
for chemotherapy in OS cell lines. Inclusion of more OS cell lines especially 
those differing in their mutational background will provide important information 
regarding calcitriol sensitization on chemotherapeutic response. The role of other 
proteins such as MMP-9, MMP-13 and MMP-28 or CXCR4 in vitamin D 
mediated effects on the migration and invasion of 143B-P need to be investigated. 
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APPENDIX A 
Principle of MMP spectrophotometric assay: 
 Can be used to screen MMP inhibitors and inducers 
 Chromogenic substrate, a thiopeptolide is cleaved by MMPs releasing 
sulfhydryl group. 
 The sulfhydryl group reacts with Ellman’s reagent (5,5’-dithiobis92-
nitrobenzoic acid) 
 Final product of this reaction is 2-nitro-5-thiobenzoic acid, can be detected 
at 412 nm. 
 
 
                                          Cleaves                                                      
                      Peptide + R-S-H (sulfhydryl)                      
                                                          Ellman’s reagent 
   Detected at 412 nm 
 
 
 
Thiopeptolide 
MMPs 
58 
 
APPENDIX B 
Glutathione reference standard plot 
Used for instrument calibration provided in MMP detection kit. 
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APPENDIX C 
Reverse transcriptase polymerase chain reaction representative cycle graph and 
melt curve  
PCR Amp/Cycle Graph for FAM-490 
 
Melt Curve Graph for FAM-490
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APPENDIX D 
 
MMP-1 primer sequences 
Reported (PS1) 
Forward: 5’-GGTGCCCAGTGGTTGAAAAAT-3’ 
Reverse: 5’-CATCACTTCTCCCCGAATCGT-3’ 
Designed (PS2) 
Forward: 5’-GCACAATCACAGCTCAATGC-3’ 
Reverse: 5’-TCATGCACCTGTAGTCCTAGTCC-3’ 
 
GAPDH primer sequence (STANDARD) 
Forward: 5’-GAGTCAACGGATTTGGTCGT-3’ 
Reverse: 5’-GACAAGCTTCCCGTTCTCAG-3’ 
 
  
 
 
 
